BioSpace News Archive

The global microsurgery robot market is envisaged to rise at an exponential CAGR due to strong technological advancement in the field.

Transparency Market Research has published a new report titled, ‘Hemoglobin A1c Testing Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

The growing demand for non-invasive lasers, coupled with the increasing advancement of technology in the healthcare sector is projected to aid in the expansion of the global alexandrite gemstone lasers market.

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing they have submitted a revised Investigational New Drug module on the manufacturing of ZYESAMI to the U.S. Food and Drug Administration, containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale.

Sanofi’s investigational oral Bruton’s tyrosine kinase inhibitor, tolebrutinib, demonstrated favorable one-year tolerability in a Phase 2b long-term extension study in patients with relapsing forms of multiple sclerosis.

Biogen Inc. announced new data from its industry-leading portfolio of multiple sclerosis therapies.

Sanofi Canada is pleased to announce that Health Canada has approved SARCLISA® in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Quantori , LLC today announced the appointment of Steve Labkoff, MD, to the position of Global Head of Clinical and Healthcare Informatics

ReForm Biologics Inc. today announced that Robert Mahoney, PhD, has been promoted to Chief Scientific Officer (CSO) and that Kevin Kavanaugh, CPA, has been promoted to Chief Financial Officer.

NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 1b study of its lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), following CAR-T cell therapy tisagenlecleucel (Kymriah®) in patients with relapsed/refractory (r/r) Large B-Cell Lymphoma (LBCL).